This brand name is authorized in United Kingdom
The drug LASILACTONE contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Spironolactone
UNII 27O7W4T232 - SPIRONOLACTONE
|
|
Spironolactone, as a competitive aldosterone antagonist, increases sodium excretion whilst reducing potassium loss at the distal renal tubule. It has a gradual and prolonged action. |
|
2
Furosemide
UNII 7LXU5N7ZO5 - FUROSEMIDE
|
|
Furosemide inhibits active chloride transport in the thick ascending limb. Re-absorption of sodium, chloride from the nephron is reduced and a hypotonic or isotonic urine produced. The evidence from many experimental studies suggests that furosemide acts along the entire nephron with the exception of the distal exchange site. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C03EB01 | Furosemide and potassium-sparing agents | C Cardiovascular system → C03 Diuretics → C03E Diuretics and potassium-sparing agents in combination → C03EB High-ceiling diuretics and potassium-sparing agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 147645, 36459 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
